LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200.00%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.01, delivering a surprise of +125%.Over the last four quarters, the company has surpas ...

LifeMD (LFMD) Q2 2025 Earnings Call August 05, 2025 04:30 PM ET Speaker0Good afternoon. Thank you for joining us today to discuss LifeMD's results for the second quarter ended 06/30/2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer and Mark Benison, Chief Financial Officer. Following management's prepared remarks, we will open the call for question and answer session.Before we begin, I would like to remind everyone that during this call, the company will make a number o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 (866) 351-5907 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) Delaware 76-0238453 (State or oth ...

Investor Presentation August 2025 NASDAQ: LFMD Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as: "believe," "expec ...

Exhibit 99.1 LifeMD Reports Second Quarter 2025 Results Conference call begins at 4:30 p.m. Eastern time today NEW YORK, August 5, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2025. Management Commentary "The second quarter of 2025 was an extremely productive quarter for LifeMD and the evolution of our telehealth platform," said Justin Schreiber, Chairman and CEO of LifeMD. "Hundreds of t ...

Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 millionTelehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 millionGenerated more than $8 million of operating cash flowPaid down $2.1 million of senior debt, exited the quarter with $36.2 million in cash and fully repaid all remaining senior debt subsequent to quarter-endEnhanced and diversified virtual care platform with nationwide launch of behavioral health offering, ...

Core Viewpoint - LifeMD, Inc. is set to report its financial results for the second quarter of 2025 on August 5, 2025, after market close, indicating ongoing transparency and engagement with investors [1]. Group 1: Financial Reporting - LifeMD will announce its financial results for the three and six months ended June 30, 2025 [1]. - The conference call to discuss these results will begin at 4:30 p.m. Eastern time on August 5, 2025 [2]. Group 2: Company Overview - LifeMD is a prominent provider of virtual primary care services, offering telemedicine, laboratory access, and pharmacy services across over 200 conditions [3]. - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a large affiliated pharmacy to enhance access to affordable healthcare [3].

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and LifeMD, Inc. (LFMD) emerging as key players providing direct-to-consumer services [1][2] Company Overview - Hims & Hers is focused on transforming health and wellness needs for consumers, while LifeMD offers cost-effective telehealth solutions for comprehensive virtual and in-home healthcare [2] - HIMS is expanding into Europe through the acquisition of ZAVA, targeting markets such as Germany and France, while LFMD's Wegovy program has enrolled over 75,000 patients, indicating strong market traction [6][8][10] Stock Performance & Valuation - Over the past three months, HIMS has increased by 67.2%, while LFMD has risen by 152.8%. However, in the past year, HIMS has gained 130.7% compared to LFMD's 102.2% [3] - HIMS has a forward price-to-sales (P/S) ratio of 4.3, above its three-year median of 2.3, while LFMD's ratio is 2.2, also above its median of 0.9 [5] Earnings Projections - HIMS expects a 170.4% growth in EPS for 2025, compared to LFMD's projected 107.6% growth [6][15][17] - The Zacks Consensus Estimate for HIMS' 2025 EPS suggests a significant improvement from 2024, while LFMD's estimate also indicates growth [15][17] Strategic Initiatives - HIMS is focusing on expanding into new specialty areas that can be treated via telehealth, such as sleep disorders and hypertension, which align with its business model [7] - LifeMD's Wegovy program integrates medication with virtual care, providing a compliant solution for weight loss therapy, which is in high demand [10][11] Financial Health - LifeMD reported first-quarter revenues of $65.7 million and net income of $1.4 million, showing a turnaround from previous losses, supported by $34.4 million in cash [12] - HIMS is utilizing proceeds from its $870 million convertible senior notes offering to support global expansion and investment in AI and personalized treatments [9] Investment Outlook - HIMS is viewed as a more stable investment opportunity with strong profitability and user engagement, while LFMD is recognized for its rapid growth and expansion [24][25] - Analysts have set average price targets for HIMS at $46.17 and for LFMD at $12.81, both indicating potential declines from their last close [20][22]

Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

Company Overview - LifeMD (NASDAQ: LFMD) is a rapidly growing telehealth company that provides subscriptions and prescriptions for chronic conditions [1] - The company has 290,000 active patient subscribers and operates across all 50 states in the United States [1] Business Model - LifeMD's business model focuses on telehealth services, which include both subscription-based and prescription services [1] Market Position - LifeMD is positioned in the telehealth industry, which is experiencing significant growth due to increasing demand for remote healthcare solutions [1]